Abstract 1906: Comprehensive genomic profiling for solid tumors

Abstract Background: Next-generation sequencing technologies provides deep knowledge into the foundation of tumors and can advance the field of precision oncology. It can be used to effectively select the treatment based on druggable genomic alterations. In the present study, we prospectively investigated the clinical utility of a CGP assay in patients with metastatic tumors of the lung, breast, gynecologic, and colon etc. Methods: Genomic profiling was done on FFPE tumor samples using Genes2Me PanCancer assay. This assay, specifically adapted for the present molecular screening, is validated for clinical use and accredited by CEIVD and based on the guidelines published by the Association for Molecular Pathology, College of American Pathologists. It is a NGS-based product especially designed to identify genomic alterations, based on Food and Drug Administration, National Comprehensive Cancer Network guideline references, European Medicine Agency approvals, European Society for Medical Oncology (ESMO), updated every 3-6 months. It Targets around 681 genes with the size of 1.7 Mb containing different biomarkers such as DNA/RNA fusions, TMB, MSI and HPV related genes. It also incudes homologous recombinational repair (HRR) related genes. This panel was also designed to identify large scale rearrangements and special biomarkers such as MET exon 14skipping. Sequencing was done on Illumina platform. Bioinformatics analysis was performed using standard GATK.v4.1.2 somatic variant calling pipeline. Results: Most of the samples were sequenced with average depth of >1000X. On target ration ranged between 82-94% with coverage % at 10X and 30X was more than 99%. In all the samples mutations were identifies with VAF ranges from 8-28%. mutations More than 50% samples have identified mutations with actionable FDA approved drugs. Conclusion: Although further studies are needed to support, this CGP assay is a noninvasive assay to guide therapeutic choice in oncology. It provides tumor heterogeneity profile that could be incorporated in routinely clinical practice. These findings may support the modification of the primary treatment in patients with metastatic solid tumors thus be the first step for future advances in precision oncology. Citation Format: Shobit Gupta, Amit Kumar, Pankaj Khanna, Rama Chandran, Samir Agarwal. Comprehensive genomic profiling for solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1906.